Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Y-3 Injection in the Treatment of Acute Ischemic Stroke Phase II Clinical Trial -- Multicenter, Randomized, Double-blind, Parallel, Placebo-controlled Phase II Clinical Trial

NCT06429384 is registered in ClinicalTrials.gov with Beijing Tiantan Hospital as lead sponsor.

NCT NCT06429384
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06429384 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Y-3 Injection in the Treatment of Acute Ischemic Stroke Phase II Clinical Trial -- Multicenter, Randomized, Double-blind, Parallel, Placebo-controlled Phase II Clinical Trial
Lead sponsor
Beijing Tiantan Hospital
Phase
Phase 2
Overall status
Completed
Start date
June 4, 2023
Completion date
December 24, 2023
Enrollment
240 (actual)
Sites
30

Conditions

As the registry lists them; a condition with its own page is linked.

acute ischemic stroke